Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company focuses on delivering established antifibrotic medicines directly to lung tissue to enhance efficacy and avoid side effects associated with systemic drug delivery. Its pipeline includes AP01 and AP02, which are in clinical development for these indications. Avalyn Pharma collaborates with patients, caregivers, and physicians to establish new standards of care in respiratory medicine.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage investors.avalynpharma.com
Sector Healthcare IR page avalynpharma.com
Tags
inhaled therapies, pulmonary fibrosis, interstitial lung diseases, antifibrotic medicines, respiratory diseases, clinical-stage, lung-targeted delivery, AP01, AP02
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable —
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 14
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure Q3 2026 Q2 2026 Q1 2026
Assets 399.296M 425.448M 135.663M
Net profit -29.655M -28.935M -26.869M
Free cash flow -26.342M -26.345M -30.209M

Figure Q3 2026 Q2 2026 Q1 2026
Share price 28.49 32.92 —
P/FCF -12 -13.85 —

Filed figures

Figure Dec 2024 Dec 2025
Balance sheet detail
Borrowings, non-current (USD) — 0.00
Lease liabilities (USD) — 1.67M
Cash and deposits (USD) 24M 52.3M
Right-of-use assets (USD) — 1.53M
Net debt (borrowings + leases - cash) (USD) — -50.6M
Reported Jun 3, 2026 Jun 3, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Initiated Phase 1 study of AP03, a fixed dose combination of nebulized pirfenidone and nintedanib, in healthy volunteers

Presented new AP01 data at ERS Congress and published detailed results from AP02 Phase 1 trials in Respiratory Research; data support Avalyn’s approach of delivering antifibrotic medicines directly to the lungs

Ended the third quarter of 2026 with $386.6 million in cash, cash equivalents and marketable securities; cash runway projected into 2029

BOSTON, MA, November 12, 2026 -- Avalyn Pharma Inc. (Avalyn or the Company, Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases today announced financial results for the third quarter ended September 30, 2026 and recent business highlights.

“As we approach year end, I’m proud of the progress we’ve made across our portfolio and the strong foundation we’ve built for what we expect to be a transformational 2027, with data anticipated across all three of our programs,” said Lyn Baranowski, Chief Executive Officer of Avalyn.

Sep 21, 2026

Results validate Avalyn’s approach of delivering established antifibrotic medicines directly to the lungs to maximize local exposure while limiting systemic exposure and improving tolerability

Findings support continued advancement of AP02 for idiopathic pulmonary fibrosis (IPF); enrollment is on track in AURA Phase 2 trial with topline data expected late 2027

BOSTON, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced that Respiratory Research has published detailed results from two Phase 1 clinical trials of AP02 (nebulized nintedanib) in healthy volunteers and patients with IPF. Topline data from the trials were previously presented at the American Thoracic Society (ATS) International Conference in May 2025.

“The publication of these Phase 1 data marks an important milestone for the AP02 program and reinforces the scientific rationale behind Avalyn's inhaled approach to treating IPF,” said Melissa Rhodes, PhD, Chief Operating Officer of Avalyn Pharma. “Our goal has always been to address what many consider the central challenge of antifibrotic therapy: delivering more drug to the lungs, where it is needed, while reducing exposure throughout the rest of the body and improving tolerability. The data published today demonstrate substantially higher predicted lung exposure alongside significantly lower systemic exposure than oral nintedanib, supporting AP02's potential to improve the therapeutic profile of this important medicine. We believe this lung-targeted approach may ultimately help patients derive greater benefits from treatment, with fewer side effects that can limit adherence to long-term therapy and impact quality of life.”

Dr. Rhodes continued, “We are encouraged by the continued progress of our AURA Phase 2 trial and the strong interest we have seen from investigators and patients across participating sites. We look forward to Phase 2 clinical data from AURA further evaluating AP02’s potential to deliver meaningful benefit for people living with IPF.”

Highlights from theRespiratory ResearchPublication

Data were generated in two randomized Phase 1 clinical studies. The first study evaluated AP02 in single ascending doses up to 2.0 mg in healthy volunteers (n=32) and patients with IPF (n=6) and included a healthy volunteer cohort receiving the approved 150mg oral dose of nintedanib (n=4). The second study evaluated AP02 in single (n=36) and multiple (n=24) ascending doses up to 8.0 mg twice daily for seven days in healthy volunteers. Safety, tolerability, and nintedanib plasma pharmacokinetics were evaluated, and AP02 and oral nintedanib bronchoalveolar lavage pharmacokinetics were assessed to evaluate lung exposure.

Published results show:

  • AP02 was generally well tolerated across both Phase 1 studies, with no serious adverse events reported. The most common treatment-related adverse events were headache, nausea and mild cough in the first study, and dizziness in the second; no treatment-related adverse events led to withdrawal from studies.

  • In all of the cohorts receiving multiple ascending doses, AP02 resulted in 10- to 56-fold lower systemic exposure than the mean steady-state exposure associated with the approved 150 mg BID oral nintedanib dose. Nintedanib systemic exposure generally increased with increasing AP02 dose.

  • Lung exposure was substantially higher with AP02 than with oral nintedanib. At a 4.0 mg dose, AP02 achieved approximately 26-fold higher predicted nintedanib peak concentration (Cmax) and overall exposure (AUC0-12) in epithelial lining fluid versus oral nintedanib dosed at 150mg.

Together, these findings demonstrate AP02's potential to achieve substantially higher lung exposure and markedly lower systemic exposure, supporting its potential to deliver both enhanced efficacy and reduced side effects compared to oral nintedanib.

Based on these data, Avalyn advanced AP02 into the AURA clinical trial. AURA is a Phase 2 randomized, double-blind, placebo-controlled trial evaluating two doses of AP02 administered twice daily in patients with IPF. The 12-week study is designed to enroll 160 patients to assess safety and efficacy; topline data are anticipated in late 2027.

The paper, titled, “Nebulized nintedanib (AP02) for idiopathic pulmonary fibrosis demonstrates favorable safety and lung lining fluid exposures: Results from two Phase 1 safety, tolerability, and pharmacokinetics studies,” was published in Respiratory Research on September 21, 2026, and can be found here.

Sep 16, 2026

BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the appointment of Robert (Bob) J. Meyer, MD, a distinguished pulmonary physician and former senior U.S. Food and Drug Administration (“FDA”) leader, to its Board of Directors (the “Board”). Dr. Meyer most recently served as Principal of Drug and Biologics Products at Greenleaf Health, now Eliquent Life Sciences.

"On behalf of the entire Avalyn team, I am thrilled to welcome Bob to our Board of Directors," said Lyn Baranowski, Chief Executive Officer of Avalyn. "As an accomplished pulmonologist and regulatory leader who spent decades shaping the development and review of respiratory therapies at both the FDA and Merck, Bob brings a rare combination of clinical, scientific, and regulatory expertise. His firsthand experience evaluating therapies at the FDA and advancing products through global development programs gives him a unique perspective on the regulatory, clinical, and strategic considerations that drive successful drug development. His guidance will be invaluable as we advance AP01, AP02, and our emerging combination therapy candidate AP03 through their next stages of clinical development and execution."

“Avalyn’s inhaled approach represents a compelling opportunity to address the tolerability challenges that limit the use of current antifibrotic therapies and offer new hope to patients living with pulmonary fibrosis,” said Dr. Meyer. “I am honored to join the Board at this pivotal stage for Avalyn. With multiple programs advancing through development, the Company is well positioned to drive meaningful progress for patients with serious respiratory diseases, and I look forward to supporting its vision of transforming the treatment paradigm for these underserved communities.”

Dr. Meyer brings more than 25 years of leadership experience spanning regulatory, academic, and industry roles. He most recently served as a Principal of Drug and Biologics Products at Greenleaf Health, a leading FDA regulatory consulting firm, advising biopharmaceutical companies on regulatory strategy, clinical development and product approvals. Prior to joining Greenleaf, he served as Director of the Virginia Center for Translational and Regulatory Sciences at the University of Virginia School of Medicine.

Before his academic career, Dr. Meyer spent more than 15 years at the FDA, including serving as Director of the Office of Drug Evaluation II within the Center for Drug Evaluation and Research, where he oversaw the review and regulation of pulmonary and allergy, metabolic and endocrine, analgesic and anesthetic, and rheumatologic drug products. Earlier in his FDA tenure, he served as Director of the Division of Pulmonary and Allergy Drug Products, following roles as a medical reviewer and team leader. He subsequently held senior leadership positions at Merck Research Laboratories, including Vice President, Global Regulatory Strategy, Policy and Safety, where he led worldwide regulatory and pharmacovigilance activities. A board-certified pulmonologist and critical care specialist, Dr. Meyer also brings significant public company and governance experience, having served on the boards of multiple biopharmaceutical companies, including Chimerix, Translate Bio, and Correvio.

Prompts

Avalyn Pharma Inc. (ticker AVLN), listed in United States.

Company History

Date Change Detail
May 8, 2020 Renamed Genoa Pharmaceuticals, Inc. → AVALYN PHARMA INC.

ETFs Holding Avalyn Pharma Inc.

ETF Weight in ETF Shares Market value As of
WCEO 0.49% 1,703 $ 49.029K Jul 31, 2026
TMED 0.18% 1,244 $ 40.952K Jun 30, 2026
TMSL 0.07% 60,717 $ 1.999M Jun 30, 2026
RESM 0.04% 45 $ 1,481.40 Jun 30, 2026
AVUS 0.00% 1,717 $ 51.098K Nov 16, 2026
AVUQ 0.00% 371 $ 11.041K Nov 16, 2026